Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Urinary Bladder Neoplasms 1Sarcoma 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Cisplatin 131Cetuximab 80Radiotherapy 76Docetaxel 59Carboplatin 46pembrolizumab 45Paclitaxel 44Fluorouracil 42Radiotherapy, Intensity-Modulated 35Drug Therapy 17Radiation 14Nivolumab 14Gefitinib 14Gemcitabine 13Surgical Procedures, Operative 12Oxaliplatin 11Erlotinib Hydrochloride 11130-nm albumin-bound paclitaxel 11Pemetrexed 10Celecoxib 10Capecitabine 10Bevacizumab 10tislelizumab 9Filgrastim 9Amifostine 9Albumin-Bound Paclitaxel 9durvalumab 7atezolizumab 7Chemoradiotherapy 7toripalimab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Head and Neck Neoplasms × bempegaldesleukin × Clear all
NCT04936841 2024-04-04

Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma

University of Wisconsin, Madison

Phase 2 Terminated
5 enrolled 17 charts
Head & Neck

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡